Cervical Cancer — Clinical Trial of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine
Citation(s)
An Open-Label, Single-dose, Non-Randomized, Safety and Tolerability Study of Recombinant Human Papillomavirus Virus 16/18 Bivalent Vaccine (E.Coli)in Healthy Female Subjects Aged 18 to 55 Years